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discontinued medication. The most commonly cited reason for
discontinuation was the medication(s) did not work well (35%);
side effects was the second most common reason (20%). Addi-
tional reasons included lack of need for frequent use (17%), cost
of treatments (11%), and dislike of taking pills all the time
(12%). When asked about medication-taking behaviors, 155
(21%) out of 752 patients taking oral medications reported skip-
ping doses. Reasons for skipping doses included forgetting to
take medication (68%), dislike of taking pills all the time (14%),
and cost of medication (10%). Of those reporting skipping doses
of medications, 41% reported this occurs every couple of weeks;
30% and 25% reported it occurs weekly and monthly respec-
tively. Only 4% reported daily skipping of doses. CONCLU-
SIONS: A signiﬁcant portion of BPH patients using oral
treatments reported discontinuing therapy due to lack of efﬁcacy
and a variety of other reasons. Skipping doses was also a
problem for over 20% of patients taking oral medications.
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OBJECTIVES: The objective of the present study is to describe
the compliance observed with a prescribed once a day placebo
over a 28 days period in adolescent healthy volunteers, in school-
dwelling youngsters in Belgium. METHODS: Eighty students
were asked to take a placebo once a day during 28 days. Tablets
supply was dispensed by sequences of 14 days either in an elec-
tronic pill box (MEMS®) or in an electronic blister pack
(Cerepak®) according to a crossover design. Both devices
allowed real time electronic compilation of dosing histories. At
the end of the study, students were asked to assess their own
compliance with a structured questionnaire. RESULTS: Compli-
ance data were available for 78 students. We observed no dif-
ference in compliance between the two monitoring devices (p =
0.682), nor between periods (p = 0.462), and no carry-over
effects (p = 0.599). 46% of the students took most of their doses
in the morning (before 10:00AM) and 49% in the evening (after
04:00PM). Compliance was higher (p = 0.016) among the stu-
dents who took their pills in the morning (92% vs 85%). Only
9 (11%) students took all of the 28 prescribed doses and 36
(46%) missed more then 5 doses. There was a strong weekend
effect. The probability to take a tablet on a Friday or a Satur-
day was reduced by 30% (p < 0.0001). Only 58% of the sub-
jects were able to estimate reasonably well their compliance with
the prescribed regimen. CONCLUSIONS: To be compliant with
drug therapy is a burden for the majority of adolescents, most
of whom are in good health and have little experience with
taking medicines. Evening and weekend discipline seems to be
problematic. No differences in compliance by measuring device
were observed. When precise assessment of compliance is crucial
for the interpretation of study results, electronic monitoring
should be used, especially in adolescent populations.
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OBJECTIVES: The recall period associated with any patient-
reported outcome (PRO) measure is critical to the interpretation
of the measure. However, the most appropriate recall period is
often unclear. The objective of this analysis was to compare
responses to two satisfaction with sexual intercourse (SSI) mea-
sures with different recall periods. METHODS: Sexual health
data and intravaginal ejaculatory latency time (IELT) were col-
lected from 1115 men and their female partners as a part of a
two-month observational study of men with and without pre-
mature ejaculation (PE) from ﬁve European countries. Data from
men diagnosed with PE are included in this analysis (n = 196).
IELT was measured by a female-operated stopwatch and
recorded by the male subject on an event log. Two single-item
measures of SSI were collected: 1) “Over the past month, was
your satisfaction with sexual intercourse: 0 = very poor, 1 = poor,
2 = fair, 3 = good, or 4 = very good?” and 2) “Were you satis-
ﬁed overall with this sexual experience?” (yes/no). Responses to
the ﬁrst item were recorded by the male subjects at the study site.
The second measure was assessed following each sexual inter-
course and recorded on the event log along with the IELT. For
this per-event item, a mean percentage SSI was computed for
each subject over a one-month period so that the recall periods
for the two measures were comparable. RESULTS: There was a
strong association between SSI measures based on one-month
recall and the percentage of satisfactory sexual experiences based
on the event log data: Very poor (Mean = 12.6%, SD = 29.4%,
n = 11), Poor (Mean = 24.0%, SD = 19.0%, n = 49), Fair (Mean
= 63.7%, SD = 25.0%, n = 66), Good (Mean = 85.6%, SD =
16.8%, n = 52) and Very good (Mean = 95.6%, SD = 7.3%, n
= 18). CONCLUSIONS: Measures of SSI assessed on a per-event
basis and using a one-month recall period are highly associated
suggesting that either measure could be used to assess outcomes
related to SSI among men with PE.
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OBJECTIVES: To evaluate barriers to communication about
erectile dysfunction (ED) and their impact on patient-reported
outcomes. METHODS: Male participants in the May 2004
internet-based National Health and Wellness Survey (NHWS)
who reported being married/living with a partner, difﬁculty
achieving/maintaining an erection but had not spoken with a
physician about ED, and taking medication for blood pressure
were recontacted in December 2004. Patients were asked
whether they had spoken with a physician about ED since the
May 2004 survey and barriers to communication about ED. ED
status and severity were conﬁrmed with the Erectile Function
(EF) domain of the International Index of Erectile Function. Data
were also collected from the SF-8, Erectile Distress Scale (EDS),
and the 2004NHWS. RESULTS: Of the 233 ED patients who
were recontacted and completed the questionnaire, 31%
reported speaking with their physician about ED. Patients who
spoke (vs did not speak) with their physician were younger (63
vs 67y, P = 0.008), had less severe ED (EF domain score, 12.1
vs 7.7, P < 0.001), and were more distressed about ED (EDS
scores, 4.1 vs 4.7, P = 0.002). Among those who spoke with their
physician, 83% initiated the discussion, and the most common
motivator was their spouse; 32% reported currently taking a
phosphodiesterase type 5 inhibitor. Fifty-seven percent of these
patients waited ≥1 year before discussing ED with their physi-
cian, most commonly because of a belief that ED was a natural
part of aging (42%). Of those who did not speak with their
